4th Quarter - Report
INNOVATIVE FEDERAL STRATEGIES, LLC for ACURX PHARMACEUTICALS, INC.
Client
Income
$20,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, 2026, Title II, all provisions related to research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| CARL KIME | — |
| LETITIA WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.